EMG
ESPR icon

Ellington Management Group’s Esperion Therapeutics ESPR Stock Holding History

Ellington Management Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,700
Closed -$209K – 461
2018
Q3 		$209K Buy
+4,700
New +$216K 0.06% 437
2018
Q2 		– Sell
-17,000
Closed -$1.23M – 600
2018
Q1 		$1.23M Buy
+17,000
New +$1.25M 0.09% 142

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ellington Management Group's ESPR Position: Q4 2018 in Review

Ellington Management Group sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 4,700 shares — an estimated $209K sold.

Ellington Management Group first reported a position in ESPR in Q1 2018 and held it in 2 quarters. The position peaked at $1.23M in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • Ellington Management Group reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ellington Management Group sold 4,700 Esperion Therapeutics shares in Q4 2018, an estimated $209K.
  • Ellington Management Group first reported a position in Esperion Therapeutics in Q1 2018 and held it in 2 quarters.
  • Ellington Management Group's Esperion Therapeutics position peaked at $1.23M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Ellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.